1Department of Hospital Pathology, The Catholic University of Korea, College of Medicine, Seoul, Korea
2Department of Pathology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
3Department of Pathology, Inje University Sanggye Paik Hospital, Seoul, Korea
4Department of Pathology, Samkwang Medical Laboratories, Seoul, Korea
5Department of Pathology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
© 2023The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethics Statement
This study was reviewed and approved by the Institutional Review Board of the Catholic University of Korea College of Medicine (UC21ZISI0138).
Availability of Data and Material
The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.
Code Availability
Not applicable.
Author Contributions
Conceptualization: YC, SSL, CSK. Data curation: YC, JAG, CSK, SSL, HJC, HJK, GP. Funding acquisition: YC. Investigation: YC, SSL. Methodology: YC. Project administration: YC. Resources: YC, CSK, SSL, HJC, HJK, GP. Supervision: SSL, GP, CSK. Validation: YC, JAG. Visualization: YC, JAG. Writing—original draft: YC, JAG. Writing—review & editing: YC, SSL, HJC, HJK, CSK, GP. Approval of final manuscript: all authors.
Conflicts of Interest
Y.C., a contributing editor of the Journal of Pathology and Translational Medicine, was not involved in the editorial evaluation or decision to publish this article. All remaining authors have declared no conflicts of interest.
Funding Statement
This study was supported by a Korean Society for Cytopathology grant (No. 2021-01).
Diagnostic reporting categories | Explanation | Post–LN-FNAC management recommendations | Exemplary findings |
---|---|---|---|
Inadequate/non-diagnostic (L1) | Low cellularity | LN-FNAC repetition and/or CNB or excision | - |
Benign (L2) | Reactive hyperplasia | Clinical F/U or specific Tx depending on the Dx | - |
Benign lymphadenitis | |||
AUS/ALUS (L3) | Possibly benign, not fully supported by cytology and ancillary technique | LN-FNAC repetition with acquisition of material for ancillary studies and/or CNB or excision | Two-cell population that cannot exclude follicular lymphoma |
Monotonously small cell population that cannot exclude low-grade B-cell lymphomas such as marginal zone B-cell lymphoma, small cell lymphoma/chronic lymphocytic leukemia, mantle cell lymphoma, and lymphoblastic lymphoma | |||
Suspicious (L4) | Possibly malignant, not fully supported by cytology and ancillary technique | LN-FNAC repetition with acquisition of material for appropriate ancillary studies and/or CNB or excision | Monotonously small and/or medium-sized, monomorphic atypical lymphoid cells suspicious of lymphoma, but cytomorphology alone is not sufficient for diagnosis, polymorphous lymphoid smears in which few Reed-Sternberg-like cells are detected, large cell or Burkitt lymphomas with scantly cellular, and smears in which atypical cells suspicious for metastasis are detected but are too scant to be diagnostic |
Malignant (L5) | (NHL, HL, metastases) | Histological biopsy requested (not requested for HL/NHL relapses or metastasis from known or clearly indicated primary tumor, etc.) | Small-to-medium-sized cells of non-Hodgkin lymphomas supported by evidence of clonality and all the entities in which cytopathological features alone are sufficient to identify malignancy as large cell non-Hodgkin’s lymphoma. This category also includes Hodgkin’s lymphoma in which there is an appropriate cellular background and diagnostic Reed-Sternberg cells as well as metastatic neoplasms |
LN-FNAC, lymph node fine needle aspiration cytology; CNB, core needle biopsy; F/U, follow-up; Tx, therapy; Dx, diagnosis; NHL, non-Hodgkin lymphoma.